Since 2015, the humanized anti-CD22 monoclonal antibody epratuzumab has been investigated for the treatment of SLE, holding promise for patients with moderate to severe active disease (142144)
Experience IV Therapy Benefits You Can Actually FEEL: Immediate energy boost and mental clarity
Prefer a plan, not a one-off
Evaluation of potential probiotics Bacillus subtilis WB60, Pediococcus pentosaceus, and Lactococcus lactis on growth performance, immune response, gut histology and immune-related genes in Whiteleg shrimp, Litopenaeus vannamei
Individual response varies based on factors including body composition, GLP-1 receptor genetics, and metabolic statenot delivery method alone
Heterogeneity of cell surface glutamate and GABA receptor expression in shank and CNTN4 autism mouse models